Georgio Mosis is Inventors, Innovator and an experience innovation leader in healthcare IT. He is a Principal Scientist at Philips Research Asia- Shanghai where he leads innovation projects in Healthcare IT Standardization, Privacy and Security, Big Data analytics, NLP, and intelligent Applications for chronic disease management and population health. Dr Mosis holds master degree and PhD in Clinical Epidemiology and Medical Informatics and an MBA in Healthcare Innovation and Marketing. He advocates a Science to Business approach that aims to match the needs identified in the clinical context with innovative technology solutions and matching innovative business models. 

Michael Hua is Director, New Business Development, Johnson & Johnson Medical based in China. He has over ten years experience in M&A and Corporate Strategy consulting. He has been involved in some of the major acquisitions at Johnson & Johnson. 

Mr. Lin Feng joined Shanghai Municipal Food and Drug Administration (SHFDA) 14 years ago, and is currently the Director of SHFDA’s Division of Medical Device Registration. He leads the development of Class I and Class II medical device initiatives on premarket review and registration related regulations in Shanghai.During his time at SHFDA since 2000Mr. Lin has done intensive work in different areas related to safety of food, drug and medical devices. He worked as a staff member in the Inspection and Investigation team for four years, then as the Deputy Commander of SHFDA’s Law Enforcement Team. He also worked at the local district level. He was the Bureau Deputy Director of Zhabei District Branch and the Director of Shanghai Zhabei Institute for Food and Drug Control for over five years. In 2007, he attended the 4th ShanghaiHong Kong Exchange Program for Civil Servants. In 2012, he studied in the Law Center of Georgetown University as a visiting scholar for half a year.Mr. Lin received a Bachelor of Science in Pharmacy in 1987 from the Second Military Medical University in Shanghai.

Xin Tang is a senior program manager at Medtronic Shanghai Innovation Center. She is responsible for establishing toxicology and biocompatibility programs within MSIC to support local product development, and to facilitate product approval and adoption in Chinese Market and other Global Market. Xin has over 7 years’ experience serving as Principal Regulatory Affairs Specialist, Sr. Regulatory Affairs Specialist, and Senior Toxicologist for both Teleflex and Medtronic in US. She is a Subject Matter Expert (SME) in the areas of biocompatibility and toxicology assessments of medical devices, health risk assessments, GLP, GMP preclinical safety study design and implementation, global regulatory submission and regulatory toxicology. Dr. Tang holds a M.B.A. in Management from University of Florida, and Ph.D. in Pharmacology and Toxicology from Medical College of Wisconsin. Dr. Tang is an American Board of Toxicology certified toxicologist and American College of Microbiology certified microbiologist. She has also got the Regulatory Affairs Certification (RAC US).

Dr. Gangfeng Xu is a seasoned business leader with more than two decades of experience in the healthcare industries.  Currently he is a Divisional Vice President, Corporate Licensing & Acquisitions with Abbott Laboratories.  Based in Shanghai, he leads Abbott’s business development activities in China for all business divisions, including pharmaceuticals, nutrition, medical devices, and diagnostics.  Prior to joining Abbott, Dr. Xu was an Assistant Vice President and Head of Licensing & Business Development for Wyeth Asia-Pacific. In this role, he led Wyeth’s company-wide business development efforts for the Asia-Pacific region.  Before joining Wyeth, Dr. Xu was an Engagement Manager at Accenture, a leading global consulting and technology company.  As a management consultant, he advised senior executives in pharma/biotech companies in developing business growth strategies and implementing transformation initiatives to improve R&D productivities and operations efficiency.

Dr. Xu received his advanced degrees in the US: an MBA from Kellogg School of Management, Northwestern University in Chicago, and a Ph.D. in human genetics from the University of Utah.  He completed his postdoctoral training at Harvard Medical School and Dana-Farber Cancer Institute in Boston, USA.  He received a BS in biology from Fudan University in China.


An Liu, M.S., is General Manager, NAMSA China. He is responsible for the establishment and development of NAMSA China business, often consulting with Chinese government officials. Previously, he was director of biostatistics and data management at NAMSA. An Liu also has served as statistics manager at Medtronic, statistician at 3M and statistician at the VA Medical Center. He was an adjunct faculty for the St. Cloud State University Master of Application Clinical Research program and an adjunct faculty for Metropolitan State University. He earned a M.S. in biostatistics from University of Minnesota, USA. He holds a M.S. in environmental biology from Peking University, China, and a B.S. in ecology from Nankai University, China.

Dr. Martin is the Vice President of Medical Research Programs at NAMSA.  He was the managing partner, chief medical officer and vice president of medical research for the Integra Group, a Minneapolis Medical Research Organization (MRO) before being acquired by NAMSA in 2012.  Dr. Martin has over 25 years of class I–III medical device development experience with 15 medical device patents issued or pending. He has helped place numerous significant medical products on the market starting from inception.


Ray Yang joined NLVC with more than 15 years of experience in direct investments, government agencies and multinational corporations. Prior to NLVC, Ray was an investment director at Orchid Asia Group and helped establish its China operations. He focused on investment opportunities in consumer product and service sectors including education, health care, and retail. Before that, Ray was a commodity trader at Louis Dreyfus Corporation, focusing on agriculture commodities. Prior to this, he was a vice commercial consul for the Consulate General of China in Houston, Texas, promoting trade and investment between China and the southern region of the United States. Previously, he worked at the Ministry of Foreign Trade & Economic Cooperation (now the Ministry of Commerce) for four years in Beijing as an operations manager, where he supervised operations of the Economic & Commercial offices of the Chinese Embassies and Consulates.Ray graduated with a Bachelor’s degree in Economics from Shanghai Institute of Foreign Trade, and has a MBA from Harvard Business School.

Mr. Qin is founder and Chairman of Shanghai Kinetic Medical Co., Ltd,a leading developer and manufacturer of minimally invasive orthopedic and cardiovascular devices. Mr. Qin is also the founder and Chairman of MedSphere International Holdings, Inc., a Shanghai based developer and manufacturer of RF equipment for minimally invasive surgeries.Prior to his business venture in China, he had been involved in several successful medical device startups in the US. He held engineering and management positions at Medtronic and B. Braun early in his career.Mr. Qin holds a B.S. in Electrical Engineering from Fudan University and a M.S. in Biomedical Engineering from the Ohio State University. He has over 30 US and Chinese patents issued to his credit.

Aiguo Wang, Ph.D.Chairman and General Manager of Trauson (China) Medical Instrument Co., Ltd.

22 years of experience in medical devices industry including 8 years in executive leadership roles; a world renowned research leader in orthopaedic biomaterials, biomechanics, biotribology, and advanced manufacturing with more than 120 scientific publications and 20 plus US patents; a visiting professor of three of China’s top universities, a 3-time winner of Stryker Corporate’s Best Invention Awards, a winner of the 2011 Ken Ludema Best Paper Award, and the 2009 Research Leader of the Year Award by the New Jersey Hi-Tech Hall of Fame; MVP Awards by Stryker Othopaedics, Major areas of contributions to orthopaedics: X3 highly crosslinked polyethylene bearing technology, Tritanium porous metal fixation technology, laser additive manufacturing and Ebeam 3D printing, the Stryker Virtual Bone Database and Analytics (SOMA); in March 2013, Dr. Wang has relocated to China from the USA to run Trauson as its General Manager

Ms.YingLuo is a Partner and Managing Director in the Beijing office of The Boston Consulting Group. Ying is a core member of BCG Greater China's Healthcare Practice and she has been with BCG for 10 years. She has over 15 years of healthcare industry and consulting experience.
Ying has consulted leading global healthcare companies in the medical technology and pharmaceutical sectors. Specifically, she has worked in all of the major sectors of the medtech industry, including diagnostic imaging, IVD, cardiovascular, OR equipment, orthopedic medical supply, healthcare IT and so on. She has a broad range of topic expertise from strategy, sales and marketing, organization, to operations etc. A few examples of her recent medtech projects in China include: 5-year growth strategy for a MNC medtech company; commercial organization strategy for a MNC DI company; sales and distribution strategy development and execution for a global medical device company in China; M&A opportunity screening for a MNC medical device company; operations strategy development and implementation for a MNC orthopedics company in China.
Prior to joining BCG, Ying worked as a consultant at ZS Associates in Illinois, U.S., a management consulting firm specializing in healthcare industry. Her project experience at ZS includes sales force optimization and marketing for global pharmaceutical and medical device companies. Ying also worked as a finance manager at GE Healthcare for four years in Beijing, China.
Ying holds an MBA degree from the Kellogg School of Management, Northwestern University and a B.A. in Finance from Peking University.

Dr. Jonathan Wang is a Senior Managing Director, Asia at OrbiMed.  With over 20 years of healthcare and life sciences experience, spanning investment, finance and research, he has co-founded OrbiMed Asia.  Previously, he was a Partner at Legend Capital and General Manager, Greater China at Burrill & Company.  He also worked for WI Harper Group, where he was a Managing Director overseeing the firm’s life sciences activities worldwide, and Walden International. He was a Board Director at ForteBio, Inc. (acquired by Pall Corporation) and is Chairman at Bonovo Orthopedics, Inc. He is a Board Director at EA, Inc. (formerly Chairman), Response Biomedical Corporation (TSE: RBM) and Waterstone Pharmaceuticals, Inc.  He is a co-founder and former Chairman of The BayHelix Group, a premier organization of Chinese life sciences business leaders. He holds a Ph.D. in Molecular Neurobiology from Columbia University, where he obtained scientific training under the supervision of Dr. Eric Kandel, a Nobel Laureate. He was rewarded the Howard Hughes Medical Institute (HHMI) Research Fellowship at Columbia. He also earned an MBA from Stanford University.

Dr. Cain specializes in the treatment of disorders of the foot and ankle. Dr. Cain's clinical interests are arthritis, bunion deformity, foot and ankle reconstruction, foot injuries, diabetic limb salvage, tendonitis, hammertoes, metatarsalgia, charcot neuroarthopathy.He is an active basic science and clinical researcher. Along with published scientific papers and presenting at numerous academic meetings, he serves as a peer reviewer for various foot and ankle journals, an abstract reviewer at scientific/research meetings and served on various organization committees. Dr. Cain research focuses on foot and ankle disorders, diabetic bone healing/limb salvage, biomechanics and clinical epidemiology 

Dr. Timothy Low is a medical doctor and the Vice President for Medical Affairs for Asia Pacific at Covidien. He manages the medical affairs, health economics and clinical development of new and current devices for the unmet needs of surgeons and patients in this region.He was the immediate-past Regional Medical Director for a top-ten pharmaceutical company and awarded the ‘Best Outstanding New Talent’ for Asia Pacific in 2007. He has also been bestowed the Clinical Trials Honor Roll for 2011 and 2012.Dr Low was the CEO of Gleneagles Hospital in Singapore, where he successfully led Gleneagles to establish itself as a 6-star private healthcare provider by clinching 14 local and regional awards including the highly prestigious Asian Hospital Management Award.He is the pioneer in Asia for the Contract Research Organisation (CRO) industry, being the first to set Covance Asia, the Asian arm of a Global CRO.Dr Low joins the prestigious ranks of Stanford Who’s Who as a result of his exceptional effort in the healthcare industry.He is a prominent and respected professional in the region for driving service excellence. He speaks regularly at national and international conferences, and has been featured on numerous television programs and magazines for his exemplary service leadership.He has held key management positions in the last 25 years with renowned organizations. With his expertise, he has not only contributed significantly to Clinical Research, but also to the pharmaceutical industry, medical device industry, as well as the medical community.



Xiao-Yan Gong received his PhD from University of California at Santa Barbara.  He is an international recognized specialist in design evaluation and durability of medical implantable devices.  He serves as a technical advisor board member for startup companies, as a technical committee member for scientific organizations and as a leader on ASTM “Fatigue to Fracture and Beyond” standard development working group, setting the durability standard for cardiovascular devices.Dr. Gong has more than 14 years of medical device design and product launching experience.  He worked in prosthesis heart valve, stent and other medical implantable device companies prior to start his current consulting firm Medical Implant Mechanics LLC (MIM).  MIM helped its clients successfully launched tens of billion dollar values of products since August 2006 in addition to consulting services and research activities for regulatory agencies, research institutes, and famous universities.  Today, MIM is an internationally recognized brand name in medical implantable device industry specializing in durability.  MIM serves as the expert committee members for a few ISO standard committees with voting rights. He was invited as guest seminar speakers for multiple universities including Stanford, Princeton, UC Berkeley, and Beijing University.  He was invited to give many lectures in international technical conferences.